Twisted Path Yields 1st Diabetes Drug Approved Since FDA Cardio Guidelines
Executive Summary
After FDA recently issued cardiovascular safety guidelines for diabetes medicines, many large drug makers returned to the clinic to revise their plans. But VeroScience, a small and relatively obscure company, won approval for its Cycloset medication to treat type 2 diabetes on the strength of Phase IIIb trial data that actually exceed FDA's standards
You may also be interested in...
Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel
There is one message that sponsors should take to heart from an FDA advisory committee's first pass at applying new cardiovascular outcomes standards to type 2 diabetes medicines: enroll sicker patients in pivotal trials
FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs
FDA's flexibility in applying its new guidance for cardiovascular safety of diabetes drugs will be tested in coming months as it reviews a handful of pending NDAs and enters into discussions about other drugs in late stages of development
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.